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Cell death is thought to contribute to progressive renal cell
depletion in diabetic nephropathy. Unbiased gene
expression profiling identified novel cell death molecules in
human diabetic nephropathy. The expression of TNF-related
apoptosis-inducing ligand (TRAIL), its decoy receptor
osteoprotegerin, and receptors Fas (a Fas ligand receptor)
and CD74 (a migration inhibitory factor (MIF) receptor) were
induced in human diabetic nephropathy. Cell culture studies
supported the functional relevance of this observation and
the relationship to a high glucose environment. To define
novel proapoptotic proteins upregulated in diabetic
nephropathy, functional genomic screens for novel apoptosis
mediators were integrated with genome-wide expression
profiling and identified candidates for further functional
analysis, including brain acid-soluble protein 1 (BASP1).
Several lines of evidence point toward induction of
endoplasmic reticulum stress response in human diabetic
nephropathy. Functional studies defining an unequivocal
contribution of endoplasmic reticulum stress to cell death in
this setting are still needed. Further comparative studies will
be required to define whether there is a specific aspect of
apoptosis in progressive human diabetic nephropathy or
whether the mechanisms are shared among all patients with
chronic kidney disease. The next challenge will be to define
the consequence of therapeutic interference of the apoptosis
pathways in diabetic nephropathy and chronic kidney
disease.
Kidney International (2010) 78, 737–744; doi:10.1038/ki.2010.270;
published online 11 August 2010
KEYWORDS: apoptosis; BASP1; CD74; diabetic nephropathy; MIF; TRAIL
MECHANISMS FOR CELL LOSS IN DIABETIC NEPHROPATHY
Diabetic nephropathy is characterized by proteinuria and
progressive loss of renal function, leading to end-stage renal
disease requiring renal replacement therapy. The pathological
substrate of diabetic nephropathy is a progressive loss of
parenchymal renal cells and extracellular matrix accumula-
tion. Recently, it has become clear that inflammation also
contributes to diabetic nephropathy.1 Unbalanced apoptotic
cell death leads to renal cell loss and has been observed in
podocytes, tubular cells, and endothelial cells in experimental
and human diabetic nephropathy.2–8 Diabetic nephropathy is
the most frequent cause of end-stage renal disease in
developed countries. Only a comprehensive understanding
of the molecular basis for renal injury initiation and
progression will allow the rational design of novel, successful
therapeutic strategies. In recent years, high-throughput
techniques exploring gene expression have uncovered novel
networked mediators that contribute to renal cell death and
may be involved in human diabetic nephropathy.4,9–12
MOLECULAR BASIS FOR APOPTOTIC CELL DEATH
Cell death is usually a response to the cell microenviron-
ment.13 Among the different forms of cell death, apoptosis is
molecularly best characterized and may be manipulated
therapeutically. Cell survival depends on the interplay
between extracellular survival factors that activate intracel-
lular survival pathways and lethal factors that activate cell
death pathways leading to apoptosis (Figure 1). A key role for
radical oxygen species in cell death and diabetic nephropathy
was recently reviewed.14
The two main pathways for apoptosis are ligation of
plasma membrane death receptors (‘extrinsic’ pathway) and
perturbation of the intracellular homeostasis (‘intrinsic’
pathway). In the extrinsic pathway, ligation of death receptors
promotes the assembly of multimolecular complexes that
include adaptor proteins and initiator caspases-8 and -10.
The intrinsic pathway involves injury to intracellular
organelles, the most important being the mitochondria.
Sentinel activator ‘BH3-only proteins’ triggers the allosteric
activation of Bax and/or Bak, which oligomerize at the
mitochondria, inducing permeabilization of the outer
mitochondrial membrane and release of proapoptotic factors
such as cytochrome c, SMAC/DIABLO and AIF, which
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promote caspase-dependent and -independent apoptosis.
Cytochrome c facilitates the oligomerization of Apaf-1 and
caspase-9 in the apoptosome multimolecular complex.
Initiator caspase oligomerization activates their enzymatic
activity and cleavage of protein substrates, thus activating
effector caspases such as caspase-3 and –7, and leading to
widespread proteolysis and commitment to cell death.
Signaling crosstalk between the intrinsic and extrinsic
pathways involves cleavage of proapoptotic BH3-only protein
Bid by caspase-8. The active fragment, tBid, translocates to
mitochondria and recruits the intrinsic pathway. Bcl2-related
antiapoptotic proteins, such as Bcl2 and BclxL, bind and
sequester activator BH3-only proteins, Bax and Bak, and may
directly inhibit Apaf-1-mediated activation of caspase-9.
Sensitizer BH3-only molecules competitively displace acti-
vator BH3-only proteins from the Bcl2 pocket. Inhibitors of
apoptosis proteins directly inhibit caspases and are, in turn,
inhibited by SMAC/DIABLO.
Endoplasmic reticulum stress leads to accumulation of
unfolded proteins in the endoplasmic reticulum and triggers
the unfolded protein response, which strives to reestablish
homeostasis.15 Thus, the unfolded protein response is
primarily an adaptive response. In resting cells, the
endoplasmic reticulum chaperone HSPA5/GRP78/BiP
(heat-shock 70 kDa protein 5/glucose-regulated protein
78 kDa) binds to endoplasmic reticulum stress sensors
(IRE1, PERK, and ATF6) and keeps them inactive. On
endoplasmic reticulum stress, HSPA5/GRP78/BiP is recruited
by unfolded proteins, thus releasing and activating PERK,
IRE1, and ATF6. PERK activation leads to translation
inhibition. IRE1 initiates the nonconventional splicing of
Xbp-1 mRNA, encoding the transcription activator XBP1,
that collaborates with active ATF6 to promote transcription
of endoplasmic reticulum chaperones, including HSPA5/
GRP78/BiP. However, under conditions of severe and
prolonged endoplasmic reticulum stress, failure to restore
homeostasis is followed by cell death, usually occurring by
apoptosis.12,13,15,16 There are three main pathways that may
contribute to endoplasmic reticulum stress-induced apopto-
sis: (a) the CHOP/growth arrest and DNA-damage-inducible
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Figure 1 | Summary of apoptotic pathways and location of some key players identified by unbiased gene expression profiling in
human diabetic nephropathy (DN). Genes upregulated in human DN include CD74, tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), FAS, brain acid-soluble protein 1 (BASP1), CD36, osteoprotegerin (OPG), heat-shock 70 kDa protein 5 (HSPA5), hypoxia
upregulated 1 (HYOU1), and X-box-binding protein 1 (XBP1) and downregulated genes include vascular endothelial growth factor (VEGF),
epidermal growth factor (EGF), and DCR3. CD74 activation by migration inhibitory factor (MIF) and other inflammatory stimuli mediate
upregulation of the lethal cytokine TRAIL. TRAIL activates the lethal receptors TRAIL receptor 1 (TRAIL-R1) and TRAIL-R2 to induce cell death.
Osteoprotegerin is a decoy receptor for TRAIL. The lethal receptor FAS is also increased in human DN. FAS mediates apoptosis on ligation by
Fas ligand (FasL). Expression of the FasL decoy receptor DCR3 was downregulated. In human DN the expression of the protective
endoplasmic reticulum stress genes HSPA5/GRP78/BiP, HYOU1/ORP150, and XBP1 was upregulated. The precise location of BASP1 action is
incompletely characterized, but inhibition of BASP1-induced apoptosis by Bax antagonists and caspase inhibitors suggests a role upstream
of mitochondrial injury. CD36 was identified by unbiased gene expression profiling as a downregulated gene in murine DN, but was found
increased in human DN. Expression of the extracellular survival factors VEGF and EGF was downregulated in human DN tubular
compartment.
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(GADD153) transcription factor, which is mainly induced via
PERK, downregulates Bcl2; (b) IRE1-mediated activation of
apoptosis signal-regulating kinase 1 (ASK1)/c-Jun NH2-
terminal kinase (JNK); and (c) activation of the endoplasmic
reticulum-localized caspase-12. The three pathways are
thought to activate the caspase cascade and may recruit the
mitochondrial pathway. However, although caspase-12 pro-
cessing is widely recognized as a marker of endoplasmic
reticulum stress, its catalytic activity is limited to self-
processing and its role in cell death has been questioned.17
In the context of diabetic nephropathy hyperglycemia may
induce or facilitate apoptosis.2,4,10,18 There are no specific
pathways for high-glucose-induced cell death. Rather, high
glucose promotes the upregulation or activation of several
molecules in the different proapoptotic pathways. Early
reports disclosed upregulation of proapoptotic molecules
such as Bax and downregulation of antiapoptotic molecules
(Bcl2 and BclxL) by high glucose in the renal cells.2 However,
high glucose regulation of cell death-related genes is more
complex than initially thought. In addition, hypoxia,
oxidative stress, inflammatory cytokines, the renin–angioten-
sin–aldosterone system, advanced glycosylation end products,
and glucose degradation products may also contribute to cell
death in diabetic nephropathy.8–10,19–22
CELL DEATH GENE EXPRESSION IN HUMAN DIABETIC
NEPHROPATHY
The European Renal cDNA Bank has characterized the
transcriptomic fingerprint of human diabetic nephropathy,
that is, the level of expression of multiple mRNAs.11 Cell
death-related genes were identified through several
approaches4,9–12 (Table 1). First, the gene ontology term
‘Cell death’ identified 66 significantly upregulated and 46
significantly downregulated genes.9 Overall, 25% of apopto-
sis-related genes were differentially regulated in human
diabetic nephropathy.9 Differentially expressed apoptosis-
related genes included those coding for cytokines, receptors,
intracellular lethal proteins and caspases. Caspase-1 and
caspase-4 were upregulated. These caspases are now widely
recognized to have mainly a proinflammatory role. In a
second approach, differentially expressed endoplasmic
reticulum stress genes were characterized.12 Finally, novel
cell death genes upregulated in diabetic nephropathy were
identified by combining the database with a functional
genomics screen for cDNAs that induce apoptosis when
overexpressed in cultured cells: 12 of the 138 full-length
cDNAs inducing cell death when overexpressed in human
embryonic kidney cells also showed mRNA transcript
induction in human diabetic nephropathy biopsies.4
DEATH LIGANDS AND RECEPTORS IN DIABETIC NEPHROPATHY
Cytokines belonging to the tumor necrosis factor (TNF)
superfamily (TNFSF) activate a superfamily of receptors
(TNFRSF) and are key regulators of cell survival, inflamma-
tion, and fibrosis. TNF/TNFSF2 had long been known to
contribute to diabetic nephropathy.1 Fas (TNFSFR6), the
receptor for Fas ligand (FasL/TNFSF6), is upregulated in
diabetic nephropathy and the proapoptotic role of FasL/Fas
in the kidney, including in diabetic nephropathy, has been
extensively studied.3,23 Unbiased gene expression profiling
confirmed the increase Fas expression in diabetic nephro-
pathy and disclosed decreased expression of the decoy FasL
receptor DCR3 (TNFSFR6b) mRNA.9 Increased Fas and FasL
protein expression was confirmed by immunohistochemistry
in human diabetic nephropathy.6 However, the two most
upregulated cell death mRNA transcripts in human diabetic
nephropathy were TNF-related apoptosis-inducing ligand
(TRAIL/TNFSF10) and its decoy receptor osteoprotegerin
(TNFRSF11B).9
TRAIL is a type II transmembrane protein with a
molecular mass of 33–35 kDa. Membrane-bound TRAIL can
be cleaved from the cell surface to form a soluble trimeric
Table 1 | Cell death genes with differential mRNA expression
in human DN4,9,12,a
Cell death (gene ontology) genes
Upregulated
Osteoprotegerin
TRAIL: TNF-related apoptosis-inducing ligand
TNFAIP8: Tumor necrosis factor-a-induced protein 8
14–3-3, Z
STAT1: Signal transducer and activator of transcription 1
Fas
APP: Amyloid precursor protein
Tubulin-b
Osteopontin
Caspase 1
CD74
EIF4G2: Eukaryotic translation initiation factor 4 g-2
NRIF3: Neurotrophin receptor interacting factor 3
TIA1: T-cell intracellular antigen 1
LOXL2: Lysyl oxidase-like 2
Clusterin
DOCK1: Dedicator of cytokinesis 1
EMP3: Epithelial membrane protein 3
Downregulated
GADD45A: Growth arrest and DNA-damage-inducible-45-a
Apolipoprotein E
Sphingosine kinase 2
Prostaglandin E receptor 3
MAPT: Microtubule-associated protein-t
PKC, z: Protein kinase C z
Upregulated endoplasmic reticulum stress genes
HSPA5/GRP78/BiP: Heat-shock 70 kDa protein 5/glucose-regulated protein
78 kDa
HYOU1/ORP150: Hypoxia upregulated 1/oxygen-regulated protein 150
XBP1: X-box-binding protein 1
Genes upregulated in DN that were identified by a functional genomics
screening as inducing cell death when overexpressed in cultured cells
EMP3: Epithelial membrane protein-3
BASP1: Brain acid-soluble protein 1
PLP2: Proteolipid protein 2 (colonic epithelium enriched)
CLDN4: Claudin 4
ITGB2: Integrin, b 2 (complement component 3 receptor 3 and 4 subunit)
Abbreviation: DN, diabetic nephropathy.
aOnly genes with at least a 1.5-fold difference in expression between DN and control
biopsies are listed.
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protein that retains the proapoptotic activity. TRAIL binds to
a complex system of four membrane-bound and one soluble
receptor.24 TRAIL receptor 1 (TRAIL-R1/TNFRSF10A) and
TRAIL-R2 (TNFSFR10B) have a functional death domain
that allows caspase activation and apoptosis induction. In
contrast, TRAIL-R3 (TNFRSF10C), TRAIL-R4 (TNFRSF10D),
and osteoprotegerin do not transduce cell death signals and
osteoprotegerin behaves as a decoy receptor. Depending on
the relative levels of the different receptors and on the cell
type, TRAIL can induce cell death, and also survival,
proliferation, and maturation. Exogenous TRAIL is more
lethal to cultured cancer cells than to normal cells, and
TRAIL-R agonists are in clinical trials as anticancer agents.25
Many normal human tissues including the kidney express low
levels of TRAIL, TRAIL-R1, and -R2, which is consistent with
the low cytotoxicity of TRAIL to most healthy tissues.
However, membrane-bound TRAIL has a higher lethal
potential than soluble TRAIL, and data from knockout mice
suggest that endogenous TRAIL may induce apoptosis in
nontumoral inflamed liver.26 In this regard, hepatotoxicity
and nephrotoxicity were observed in preclinical studies
with TRAIL agonists.27 TRAIL also has immunoregulatory
functions that may be beneficial for the onset of autoimmune
diabetes.28
Osteoprotegerin is a secreted protein with no transmem-
brane domain, which is produced as a monomer
(55–62 kDa), undergoes homodimerization, and is secreted
as a disulfide-linked homodimeric glycoprotein of
110–120 kDa.29 Osteoprotegerin is a soluble decoy receptor
for both TRAIL and receptor activator of nuclear factor-kB
ligand (RANKL/TNFSF11) and may have independent
functions promoting endothelial cell survival and angiogen-
esis. Potential cross-regulatory mechanisms involving the
balance TRAIL–osteoprotegerin–RANKL may exist. Although
the affinity of TRAIL for osteoprotegerin is weaker than for
the lethal TRAIL receptors, there is evidence for the biological
relevance of the interaction.30 On a tissue level, osteoprote-
gerin regulates bone mineral density and vascular calcifica-
tion, and serum osteoprotegerin levels are increased in
patients with renal dysfunction, including diabetic nephro-
pathy, and are associated with adverse cardiovascular
outcomes.31
In the normal kidney, TRAIL is expressed in tubules but
not in glomerular cells.9 In diabetic nephropathy, TRAIL and
osteoprotegerin mRNA expression is increased and correlates
to clinical and histological severity of renal disease.9 Tubular
epithelium is the predominant nephron cell lineage expres-
sing TRAIL protein, but de novo protein expression in
podocytes was also noted in diabetic nephropathy.9,10 High
glucose did not modulate TRAIL expression in cultured
renal cells. However, proinflammatory cytokines such as
interferon-g, TNFa, and migration inhibitory factor (MIF)
increased TRAIL expression in cultured renal tubular cells
and podocytes.9,10 TRAIL promoted a modest increase in
tubular cell and podocyte death, which is consistent with a
role in the chronic progression of diabetic nephropathy seen
humans. Nuclear factor-kB activation by TRAIL protected
cells from TRAIL lethality.9 In this regard, both TRAIL and
TNF activate simultaneous death and survival signals, and
this may underlie the low sensitivity of non-neoplastic cells to
both cytokines unless the microenvironment is unfavorable
for survival. Blockade of nuclear factor-kB-mediated survival
signals or additional environmental death signals, such as
high glucose or inflammation, increase the rate of cell
death.9,10 Osteoprotegerin, even endogenous osteoprotegerin
secreted by tubular cells, protected from TRAIL-induced cell
death.9 The end result of the increased expression of TRAIL and
osteoprotegerin in a particular patient may depend on the
relative balance between them. We hypothesize that a misbalance
toward TRAIL may result in tissue injury. If osteoprotegerin
prevails, the cells would be protected from TRAIL.
Podocyte overexpression of the macrophage MIF cytokine
results in podocyte injury and proteinuria.32 MIF was
increased in experimental diabetic nephropathy, and serum
MIF was elevated in patients with diabetic nephropathy
(reviewed in Sanchez-Nino et al.10). The protein expression
of the MIF receptor CD74 is increased in tubular cells and
podocytes in human diabetic nephropathy, and CD74 mRNA
expression is increased in diabetic nephropathy.10 MIF did
not promote renal cell apoptosis. However, MIF engagement
of CD74 activated MAP kinases and increased TRAIL
expression.10 CD74 may have MIF-independent functions,
as it is a coreceptor for CXCR4 or CD44.33 These functions
have not been fully characterized in renal cells.
Microarray-based gene expression profiling on whole
kidney RNA, together with supervised clustering methods,
identified CD36 as a downregulated mRNA in diabetic mice
with albuminuria.8 CD36 protein was absent from proximal
cells, both in control and diabetic mice. In contrast, CD36
protein was upregulated and colocalized with apoptotic
proximal tubular cells in human diabetic nephropathy. This is
one of several examples of dissociation in the molecular
signature of human and experimental diabetic nephropathy.
CD36 is a class B scavenger receptor. Cell culture studies
disclosed that high glucose upregulated CD36 mRNA and
protein, and engagement by glycated albumin transduced a
lethal signal to human proximal tubular cells. Cell death was
prevented by caspase-8, but not by caspase-9 inhibition,
suggesting a role for death receptors. However, the molecular
pathways were not further characterized.
MITOCHONDRIAL STRESS IN DIABETIC NEPHROPATHY
Mitochondrial stress has long been known to contribute to
high-glucose-induced apoptosis. Increased Bax expression
was the first apoptosis-related molecular change observed
in kidney cells in response to high glucose, and Bax
knockout mice are protected from high-glucose-induced cell
death.2,18
More recently, a novel proapoptotic role has been
identified for brain acid-soluble protein 1/cortical cytoskele-
ton-associated protein of 23 kD (BASP1/CAP-23).4 BASP1 is
a multifunctional protein involved in cytoskeletal and lipid
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raft dynamics, as well as in the nuclear regulation of
transcription. BASP1 expression is mainly cytoplasmic in
some cell types including tubular cells, and nuclear in others,
such as podocytes.4,34 In the adult kidney podocyte, BASP1 is
a transcriptional cosuppressor of WT1.34 Kidney BASP1 was
upregulated at the mRNA and protein level in human and
experimental diabetic nephropathy.4 Tubular cells were the
main site of BASP1 upregulation, where it localized to
apoptotic cells.4 In cultured human tubular epithelial cells,
lethal stimuli such as serum deprivation, high glucose, or
proinflammatory cytokines increased BASP1 mRNA and
protein.4 Overexpression of BASP1 was sufficient to induce
apoptosis in tubular cells. In addition, BASP1 knockdown
protected tubular cells from apoptosis induced by serum
deprivation or high glucose concentrations, but not from
cytokine-induced apoptosis.4 Thus, BASP1 may be critical for
cell stress-induced apoptotic cell death. BASP1 is upregulated
in other forms of renal injury, such as hypertensive
nephropathy, but shows the most robust induction in
diabetic nephropathy.4 The precise role of BASP1 in the
apoptotic pathway is unclear. Interestingly, BASP1 colocalizes
with the apoptotic actin ring and tubulin in the cell cortex,
suggesting that the cytoskeleton-binding properties of BASP1
may be associated with its lethal action.4 Cytoskeletal
remodeling is a hallmark of apoptosis, and changes in actin
dynamics contribute to mitochondrial injury and cell
death.35 Prevention of BASP1-induced apoptosis by Bax
antagonists and caspase inhibitors suggests that BASP1 has a
role upstream of mitochondria or caspase activation, or that
BASP1 contributes to a positive feed-back loop, leading to
further mitochondrial injury and caspase activation.4 BASP1/
CAP-23, GAP-43 and MARCKS belong to a protein family
characterized by the presence of an effector domain,
association with the cortical cytoskeleton, and regulation of
actin-binding proteins regulated by reversible phosphoryla-
tion of the effector domain by protein kinase C.36 Interest-
ingly, different isoforms of protein kinase C have been
involved in diabetes-associated apoptosis.37
Deprivation of survival factors is a known inducer of
apoptosis that cooperates with the presence of lethal factors
such as cytokines and toxins to promote renal cell death.13 In
human diabetic nephropathy, the expression of two cytokines
with survival activity of renal epithelial cells, vascular
endothelial growth factor-A and epidermal growth factor,
was reduced at the mRNA and protein level in the tubular
compartment.13,38 In glomerular endothelium, receptor-
bound vascular endothelial growth factor protein was
decreased in more advanced lesions.7 The reduced vascular
endothelial growth factor-A expression contrasted to pre-
viously reported findings in experimental models. Reduced
renal epidermal growth factor mRNA and had been
previously observed in animal models.39
ENDOPLASMIC RETICULUM STRESS IN DIABETIC NEPHROPATHY
Stimuli that increase the demand on the endoplasmic
reticulum to synthesize proteins or degrade improperly
folded proteins cause endoplasmic reticulum stress.40 High
glucose, free fatty acids, albumin, nephrotoxins, oxidative
stress, or inflammation induce endoplasmic reticulum stress
in renal cells.12,16,41 In human progressive diabetic nephro-
pathy, expression of mRNA for protective endoplasmic
reticulum chaperone proteins HSPA5/GRP78/BiP and
HYOU1/ORP150 (hypoxia upregulated 1/oxygen-regulated
protein 150) and for the prosurvival transcription factor
XBP1 (X-box-binding protein 1) was increased.12 Increased
HSPA5/GRP78/BiP and HYOU1/ORP150 protein expression
was confirmed at the protein level. However, potentially
lethal unfolded protein response mRNAs, such as CHOP,
were unchanged or repressed.12 The finding of increased
mRNA levels for genes involved in the protective responses of
the unfolded protein response, but not for proapoptotic
genes, suggests that the endoplasmic reticulum stress in
human diabetic nephropathy might be adaptive and, per se,
does not support a role of endoplasmic reticulum stress in
progression of diabetic nephropathy.40 In this regard,
induction of some potentially lethal endoplasmic reticulum
stress proteins may not be followed by completion of the
endoplasmic reticulum stress pathway.16,41 Thus, cyclosporin
A increased CHOP/GADD153 protein expression in tubular
cells, but failed to result in caspase-12 processing, indicating
that CHOP upregulation may be induced by nonendoplasmic
reticulum proapoptotic stressors. However, it is conceivable
that interference with adaptive mechanisms, because of the
influence of genetic background or additional insults, may
result in endoplasmic reticulum-mediated cell death in
human diabetic nephropathy.
In animal models there is evidence that endoplasmic
reticulum stress-induced apoptosis may cause tubular cell
injury (reviewed in Sanz et al.13). Thus, the endoplasmic
reticulum stressor tunicamycin induced severe histological
tubular injury, which was decreased both in CHOP/
GADD153 and caspase-12 knockout mice.42,43 Furthermore,
there is evidence that impairing the adaptive endoplasmic
reticulum response, as is the case for HSPA5/GRP78/BiP-
mutant heterozygous mice, results in more severe tubuloin-
terstitial injury in response to albuminuria.44 However, there
is no functional evidence yet that endoplasmic reticulum
stress, in the presence of an intact adaptive endoplasmic
reticulum stress response, contributes to renal cell apoptosis
in vivo in animal models of proteinuric kidney disease.45 This
is in part due to technical difficulties, given the relative
paucity of adequate mouse models. To complicate matters
further, significant differences in the endoplasmic reticulum
stress response between human and experimental diabetic
nephropathy preclude direct extrapolation of animal model
results to the human situation. As in humans, increased
expression of adaptive endoplasmic reticulum stress proteins,
such as HSPA5/GRP78/BiP, has been observed in murine and
rat models.46,47 Although early studies did not find increased
caspase-12 in db/db mice,48 a recent transcriptomics-based
approach identified caspase-12 as an upregulated mRNA in
this model.47 Caspase-12 protein was processed and increased
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expression was noted in apoptotic tubular cells in vivo.
Caspase-12 was also increased in rat streptozotocin-induced
diabetic nephropathy.46 Furthermore, albumin induced
caspase-12-dependent apoptosis in cultured human HK2
tubular cells. However, most humans carry a single-nucleo-
tide premature stop codon polymorphism that inactivates
caspase-12.49 In this regard, although HK2 cells carry the
inactive caspase-12 allele, they expressed a full-length protein,
probably as a result of translational readthrough induced by
aminoglycosides in the cell culture media. Thus, the relevance
of these findings to human diabetic nephropathy is unclear,
with the exception of the 20% of the population of African
descent that expresses a functional protein. In contrast to
humans, pro-death CHOP/GADD153 mRNA and protein
was increased in animal models of diabetic nephropathy.46,47
SPECIFICITY OF THE OBSERVED CHANGES IN GENE
EXPRESSION FOR HUMAN DIABETIC NEPHROPATHY
Exposure to a high glucose environment for a few hours will
increase CD74 and BASP1, but not TRAIL expression, in
cultured tubular cells. At present, it is not possible to
differentiate whether these changes are a consequence of
diabetes, nephropathy, or diabetic nephropathy in humans.
However, there is a progressive gradient for magnitude of
changes in the expression of these genes between early and
late diabetic nephropathy.9 The fact that inflammatory
cytokines can induce the expression of these genes in
cultured cells suggests a role beyond diabetic nephropathy
and indicates that, once a threshold of kidney injury is
reached, these genes might be important for progression of
diabetic nephropathy even when an adequate glycemic
control has been achieved. In any case, there appears to be
a specific interaction between high glucose concentrations
and sensitivity to TRAIL or BASP1-induced death.4,9
There is a limited understanding of the range of human
nephropathies that present with changes in the expression of
genes such as TRAIL, CD74, or BASP1. Data from our group
and a search of the Nephromine database (www.nephromine.
org) indicate that some of these changes are present in other
proteinuric progressive nephropathies, but not present or
milder in nonprogressive proteinuric kidney injury. BASP1
mRNA expression is increased in membranous nephropathy
and age-related chronic kidney injury, and a trend was
observed for hypertensive nephropathy. BASP1 did not
change in IgA nephropathy or minimal change disease.4,50
Upregulation of TRAIL and osteoprotegerin mRNA in
age-related chronic kidney injury and minimal change
disease was significant but milder than in human diabetic
nephropathy.11,50 Fas mRNA was increased in age-related
chronic kidney injury, but not in minimal change disease.11,50
CD74 mRNA was increased in hypertensive nephropathy and
age-related chronic kidney injury, but not in minimal change
disease.4,50 In contrast, evidence for endoplasmic reticulum
stress, including increased expression of CHOP/GADD153
(not found upregulated in human diabetic nephropathy) and
HSPA5/GRP78/BiP, has been observed in a variety of
proteinuric nephropathies.45
Proximal tubular CD36 expression was not observed in
focal segmental glomerulosclerosis, but other human diseases
were not tested.8 There are additional ligands for CD36, not
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Figure 2 |Hypothetical contribution of novel cell death pathways to human diabetic nephropathy (DN): integration of
inflammation and high glucose. Renal cell loss by apoptosis is thought to contribute to the progression of DN. Both inflammation and
high glucose are known inducers of apoptosis. Renal cell culture studies suggest that inflammation contributes to increased tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) and Fas expression. Thus, migration inhibitory factor (MIF) activation of CD74 or tumor
necrosis factor (TNF) increased TRAIL expression and TNF increases Fas expression. In contrast hyperglycemia increased CD74 expression,
increased brain acid-soluble protein 1 (BASP1) expression, and also sensitized to the lethal effect of TRAIL on renal cells. Osteoprotegerin
(OPG) antagonized the lethal effect of TRAIL in cultured cells. BASP1 had a role in hyperglycemia- and growth factor deprivation-induced
apoptosis. Low levels of the survival factors vascular endothelial growth factor (VEGF) and endothelial growth factor (EGF) were observed in
human DN and may also contribute to apoptosis sensitization.
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specific for diabetes, such as thrombospondin-1, that also
promote tubular cell apoptosis.8
INTEGRATIVE VIEW AND FUTURE PERSPECTIVES
Recent evidence gathered from the direct study of gene
expression patterns in human diabetic nephropathy coupled
with confirmation at the protein expression level have
unraveled a set of new molecules and pathways, and novel
information on known players in kidney epithelial cell death.
Thus, the interplay among high glucose, inflammation, and
lack of survival factors may contribute to activation of death
receptor, mitochondrial injury, and endoplasmic reticulum
stress pathways that may ultimately lead to renal cell loss
(Figure 2). Within each of these pathways, we find a balance
of intracellular lethal and adaptive responses. Thus, poten-
tially lethal cytokines such as TNF and TRAIL also activate
prosurvival nuclear factor-kB, and current data indicate an
adaptive pattern of endoplasmic reticulum stress response
genes observed in human diabetic nephropathy. Additionally,
increased expression of some decoy receptors has been
observed. The net end result observed in vivo is progressive
loss of renal parenchymal cells in a significant proportion of
patients. The molecular networks deduced from these studies
provide a paradigm for understanding cell death regulation
in the course of diabetic nephropathy. A high glucose level
appears to have a role as sensitizer to cell death. Subsequent
features of diabetic nephropathy, such as the presence of
albuminuria and renal inflammation, are key additional
triggers of cell death and may drive the process even if
adequate control of blood glucose levels is reestablished,
providing a strong rational for antiapoptotic or antiinflam-
matory strategies in diabetic nephropathy.
Different to previous approaches, recent progress in
identification of molecules of potential pathogenic importance
has been based on the analysis of human diabetic nephropathy.
Changes in the expression of most, but not all, newly identified
genes are also observed in animal models of diabetic
nephropathy, setting the stage for preclinical intervention on
some molecules. These studies will clarify whether any of the
reported gene changes is a legitimate therapeutic target. It is
conceivable that, in the future, multipronged approaches to
the management of diabetic nephropathy may include
strategies to prolong renal cell survival.
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